Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies
Pomalidomide synergizes with CAR-T by directly enhancing CAR-T function (memory, cytokine/chemokine production, metabolic fitness, and reduced exhaustion) and remodeling the suppressive immune microenvironment (increased cytotoxic effectors, diminished MDSC activity). These findings provide a crucial mechanistic rationale for optimizing pomalidomide-CAR-T combinations in refractory lymphoid malignancies.
Authors
- Cheng Qian
- Xin Li (ORCID: https://orcid.org/0000-0001-9024-7522)
- Liwen Wang (ORCID: https://orcid.org/0000-0003-1239-4927)
- Jing Liu (ORCID: https://orcid.org/0000-0001-5588-3865)
- Yi Zhou (ORCID: https://orcid.org/0000-0002-5734-8855)
- Chang Zhang (ORCID: https://orcid.org/0000-0002-5443-8951)
- Yuhan Yan
- Linzhi Xie
- Yan Yu (ORCID: https://orcid.org/0009-0001-1551-3445)
Institutions
- Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1007/s00262-025-04247-1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Central South University
- Beijing Medical and Health Foundation
- Fundamental Research Funds for the Central Universities